$4.01
6.09% today
Nasdaq, Dec 11, 09:13 pm CET
ISIN
US67022C1062
Symbol
NCNA

NuCana plc Sponsored ADR Stock price

$4.27
+0.60 16.35% 1M
-24.43 85.12% 6M
-233.73 98.21% YTD
-251.73 98.33% 1Y
-3,775.73 99.89% 3Y
-23,495.73 99.98% 5Y
-80,745.73 99.99% 10Y
-80,745.73 99.99% 20Y
Nasdaq, Closing price Wed, Dec 10 2025
-0.01 0.23%
ISIN
US67022C1062
Symbol
NCNA
Industry

Key metrics

Basic
Market capitalization
$17.8m
Enterprise Value
$-15.8m
Net debt
positive
Cash
$33.8m
Shares outstanding
35.9b
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.8
P/B
0.5
Financial Health
Equity Ratio
40.3%
Return on Equity
-319.1%
ROCE
-74.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-25.4m | -
EBIT
$-25.8m | $-37.9m
Net Income
$-36.8m | $-356.8b
Free Cash Flow
$-18.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
36.4% | -
EBIT
36.5% | -23.1%
Net Income
-5.8% | -1,403,602.2%
Free Cash Flow
-15.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
$0.0
Short interest
0.0%
Employees
21
Rev per Employee
$0.0
Show more

Is NuCana plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

NuCana plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a NuCana plc Sponsored ADR forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a NuCana plc Sponsored ADR forecast:

Buy
75%
Hold
25%

Financial data from NuCana plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 10 10
31% 31%
-
- Research and Development Expense 16 16
51% 51%
-
-25 -25
36% 36%
-
- Depreciation and Amortization 0.43 0.43
41% 41%
-
EBIT (Operating Income) EBIT -26 -26
37% 37%
-
Net Profit -37 -37
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about NuCana plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NuCana plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
one day ago
Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings Data Presented at ESMO IO 2025 include Partial Responses, Durable Disease Control, and No New Safety Signals, Reinforcing Earlier Findings
Neutral
GlobeNewsWire
28 days ago
Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced fin...
Neutral
GlobeNewsWire
about one month ago
EDINBURGH, United Kingdom, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced that the China National Intellectual Property Administration (“CNIPA”) has granted an important patent covering the composition of matter for NUC-7738.   This patent (ZL 202010794701.2) is expected to serve as a key component of the patent protection for NUC-7738, which c...
More NuCana plc Sponsored ADR News

Company Profile

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Head office United Kingdom
CEO Hugh Griffith
Employees 21
Founded 1997
Website www.nucana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today